The price of a GLP-1 depends on which of roughly six numbers you happen to be looking at. Wegovy has a list price of $1,349 per month, and Zepbound, $1,087. Your coworker pays a $25 copay. Your neighbor pays $299 in cash. Someone on Reddit swears they pay nothing.
None of those is the number that matters, because what wrecks a GLP-1 budget is not the monthly price. It is the duration. This is a recurring expense with no scheduled end date, attached to a coverage arrangement that gets renegotiated every year without your input. That combination deserves more planning than a car payment, and most people give it less.
Price The Maintenance Dose, Not The Starter Dose
Cash prices have fallen hard. The federal direct-to-consumer site lists manufacturer cash prices for GLP-1 medications well below list price: the Wegovy pill at $149 a month, the Wegovy and Ozempic pens at $199, and the Zepbound vial starting at $299. Those numbers are real, and they are also the floor rather than the number you will settle at. The pen offers apply to the first two fills at the lowest strengths before stepping up, and vial pricing rises with dose. Almost everyone titrates upward over the first few months, so the honest budget line is whatever your maintenance dose costs in month six, not what the introductory box costs in week one.
Even at these prices, affordability is the main reason people quit. KFF national polling on GLP-1 affordability found that 56% of users, including 55% of insured users, said the drugs were difficult to afford, and 14% of users had already stopped taking them because of cost. That last figure is the one worth sitting with. Stopping because of price is not a neutral outcome, and the money already spent does not come back.
Employer Coverage Is The Biggest Variable And The Least Stable One
If your plan covers the weight-loss drug, your cost drops by an order of magnitude. Most plans do not. Employer coverage rates for weight-loss GLP-1s sat at 19% among firms with 200 or more workers in 2025, rising to 43% at firms with 5,000 or more, while roughly 34% of people under 65 with employer coverage would medically qualify for the drugs. The gap between who qualifies and who is covered is enormous, and it is why two people with the same diagnosis and the same job title can face a tenfold difference in annual cost.
Coverage also comes with conditions. Prior authorization is near universal, BMI thresholds are common, and many employers require documented participation in a lifestyle program first. More importantly for budgeting purposes, these decisions get revisited every plan year. An employer facing a pharmacy spend problem can drop weight-loss coverage at renewal while keeping the same diabetes drug coverage. If your entire budget is based on a $25 copay, you are one benefits memo away from a $300-$450 monthly bill.
Buying your own coverage complicates this further. The logic that pushes a bronze high-deductible plan for self-employed buyers works beautifully when you are a light healthcare user and want the lowest premium plus HSA access. It works against you here, because a high deductible means you pay the full negotiated price of a $1,000 drug until you have spent thousands out of pocket. If a GLP-1 is on your horizon, compare the formulary tier and deductible math before open enrollment, not after.
The HSA Is The One Lever That Works In Nearly Every Scenario
Prescription GLP-1s can be paid for with pre-tax dollars, but the rule is narrower than most people assume. Weight-loss treatment qualifies as a medical expense under IRS rules only when it treats a specific disease diagnosed by a physician, such as obesity, hypertension, or heart disease. Weight loss pursued for appearance or general well-being does not qualify. In practice, this means the diagnosis in your chart is doing real financial work, and it is worth keeping documentation in case anyone ever asks.
The savings are straightforward arithmetic. Paying $299 a month out of pocket costs about $3,600 a year in after-tax money. Running the same spend through an HSA at a combined federal and state marginal rate of 27% saves close to $1,000 annually, before counting the payroll tax savings available through an employer plan. That is the same triple-tax advantage of an HSA applied to a recurring pharmacy expense rather than to a surprise medical bill.
There is a real tension here worth naming. If you have been treating your HSA as a stealth retirement account, spending it on a monthly prescription forfeits decades of tax-free growth on that money. Neither choice is wrong. But make it deliberately, and if you can afford to pay cash and leave the HSA invested, keep the receipts. Nothing stops you from reimbursing yourself years later.
The Grocery Savings Are Real, And Smaller Than The Internet Suggests
Appetite suppression does show up in spending. Cornell researchers matched GLP-1 survey responses to transaction records from a panel of about 150,000 households and found that household grocery spending after starting GLP-1s fell an average of 5.3% within six months, more than 8% among higher-income households, with spending at fast-food restaurants and coffee shops down roughly 8%. On a $600 monthly grocery bill, that 5.3% is about $32. Add a similar cut to takeout, and you might recover $50 to $80 a month. Useful, and nowhere near enough to fund the prescription.
The composition of the basket shifts more than the total. Savory snacks fell by about 10% in the Cornell data, with sweets and baked goods close behind, while yogurt, fresh fruit, and nutrition bars rose. That shift is the whole story: when appetite drops, the binding constraint shifts from calories to nutrients, and getting more nutrition from smaller meals means leaning on fiber, protein, and healthy fats, which generally cost more per calorie than the packaged snacks they replaced. Budget the grocery line as a reallocation rather than a rebate.
Then there are the line items nobody mentions in the pitch. Telehealth platforms that bundle prescribing often charge a monthly membership on top of the drug. Lab work and follow-up visits have their own cost-sharing. And if the treatment works, replacing a wardrobe two sizes down is a genuine, if pleasant, expense.
Budget as Though You Will Be On It For Years
The strongest argument for treating this as a permanent line item comes from the trial data. In the STEP 1 extension published in Diabetes, Obesity and Metabolism, weight regain after semaglutide withdrawal accounted for roughly two-thirds of the weight lost within a year after discontinuation, with cardiometabolic improvements drifting back toward baseline as well. Participants ended the study at 5.6% below their starting weight, compared with 17.3% during treatment. Obesity behaves like a chronic condition, and the medication behaves like a chronic-condition drug.
Which means the worst financial outcome is not paying too much. It is paying for eighteen months, hitting a price increase or a coverage change you cannot absorb, stopping, and regaining most of what you paid for. A Navitus Health Solutions survey of 2,000 current and recent GLP-1 users in 2026 found that nearly half would pause retirement contributions or take on debt before quitting the medication, which tells you how forced that choice feels once you are in it.
Three moves make the expense survivable. Build a sinking fund covering six months of the full cash price at your maintenance dose, so a coverage change is an annoyance rather than a crisis. Re-verify your formulary tier at every open enrollment, since a drug covered in January may fall into an excluded class the following year. And fund the expense from ordinary cash flow rather than from your retirement contributions, because a decade of missed compounding is a much larger number than the drug.
The medications are legitimately effective and, for the first time, priced within reach of a normal household budget. They are just not a diet expense that ends when the weight does. Plan for a version of this that runs for years and whose math holds up. Plan for six months, and it will not.
Make Sure The Math Works Long Term
GLP-1 medications can be effective enough to justify a significant place in a household budget, but affordability should be measured in years rather than months. The introductory price, current copay, or savings from eating less matters far less than whether the maintenance cost remains manageable if insurance coverage changes or treatment continues longer than expected.
Before starting, work out what the medication would cost at the maintenance dose, what you would pay without your current coverage, and how much room that expense leaves for savings and other financial priorities. A GLP-1 does not need to be inexpensive to fit into a budget. It needs to be sustainable.
Leave a Reply